Daniel Tan
Psychiatry · Houston, TXNPI 1811193766
Payments from drug & device makers
Across 1,505 payments — averaging $164.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$82K
- Supernus Pharmaceuticals, Inc.$82K
- Tris Pharma Inc$42K
- Noven Pharmaceuticals, Inc.$9K
- Corium, LLC$6K
- Noven Therapeutics, LLC$4K
- plus $22K from 24 others
What the payments were for
- Consulting fees$6,0102%
- Speaking & faculty fees$175,15171%
- Grants$2,2001%
- Travel & lodging$25,98110%
- Food & beverage$37,99715%
- Education$1310%
- Gifts$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 230 | $82,299 |
| Supernus Pharmaceuticals, Inc. | 203 | $82,175 |
| Tris Pharma Inc | 167 | $42,111 |
| Noven Pharmaceuticals, Inc. | 10 | $8,937 |
| Corium, LLC | 115 | $6,473 |
| Noven Therapeutics, LLC | 41 | $3,564 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 123 | $3,057 |
| Otsuka America Pharmaceutical, Inc. | 108 | $2,956 |
| Sunovion Pharmaceuticals Inc. | 94 | $2,907 |
| Teva Pharmaceuticals USA, Inc. | 52 | $2,232 |
| Alkermes, Inc. | 42 | $1,606 |
| Johnson & Johnson | 42 | $1,557 |
| Lundbeck LLC | 55 | $1,252 |
| Vanda Pharmaceuticals Inc. | 29 | $920 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $888 |
| E.r. Squibb & Sons, L.L.C. | 25 | $867 |
| Axsome Therapeutics, Inc. | 21 | $783 |
| AbbVie | 27 | $701 |
| Validus Pharmaceuticals LLC | 14 | $558 |
| Neurocrine Biosciences, Inc. | 10 | $349 |
| Rhodes Pharmaceuticals L.p. | 15 | $329 |
| Indivior Inc. | 9 | $264 |
| Luye Pharma (USA) Ltd. | 2 | $145 |
| Shire North American Group Inc | 7 | $142 |
| Bioxcel Therapeutics, Inc. | 3 | $124 |
| Vertical Pharmaceuticals, LLC | 6 | $113 |
| Adlon Therapeutics L.p. | 6 | $105 |
| Neos Therapeutics, LP | 2 | $39 |
| Bausch Health US, LLC | 1 | $18 |
| Neuronetics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$74,160
- JORNAY PM$53,032
- Dyanavel XR$39,153
- Jornay PM 20mg capsules (Bottle of 100)$25,804
- Xelstrym$11,883
- Quillichew ER$6,252
- Quillivant$5,841
- Azstarys$4,270
- ARISTADA$2,886
- LATUDA$1,193
- LYBALVI$967
- CAPLYTA$753
- ARISTADA INITIO$722
- Quillivant XR$650
- ABILIFY MAINTENA$615
- INVEGA SUSTENNA$468
- Austedo XR$439
- AUSTEDO$370
- Fanapt$368
- Auvelity$351
How this compares
$247,489 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $77,774 |
| PerserisRisperidone | 12 | $38,966 |
| ZyprexaOlanzapine | 23 | $21,683 |
| Lurasidone Hcl | 35 | $11,794 |
| Aripiprazole | 18 | $3,280 |
| Fluphenazine Decanoate | 14 | $1,842 |
| Divalproex Sodium ErDivalproex Sodium | 28 | $1,421 |
| Quetiapine Fumarate | 33 | $1,319 |
| Olanzapine | 11 | $509 |
| Sertraline Hcl | 43 | $272 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $242 |
| Trazodone Hcl | 23 | $219 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 12 | $183 |
| Zolpidem Tartrate | 33 | $154 |
| Benztropine Mesylate | 13 | $142 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $349 | $77,77411 claims |
| Indivior Inc.Perseris | $264 | $38,96612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$3M
- Lawrence GinsbergHouston$2.4M
- Asim ShahHouston$2.2M
- Aqeel HashmiHouston$1.3M
- Robert EarleHouston$1.1M
- Frank ChenHouston$941K
- Joao de QuevedoHouston$890K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.